Skip to main content
Equibles
PCRX logo

PCRX · Pacira BioSciences, Inc. · Analyst Estimates

Track PCRX — free

Use PCRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PCRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$36.39 -0.01 (-0.03%) At close · Oct 28 Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.45B
Shares
39.86M
Volume · Oct 28 914.06K Avg daily vol (3M) 1.24M

Analyst Estimates

Compare analyst forecasts for Pacira BioSciences, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-15 23:23 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
2.72
2.90
2.99
9
2.89
2.89
2.95
2.88
1
0
1
1
Revenue
USD
Publication date not stated
747.83M
754.33M
759.40M
8
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
3.05
3.46
3.94
9
3.44
3.44
3.49
3.65
1
0
1
1
Revenue
USD
Publication date not stated
761.82M
790.02M
812.70M
8
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
0.52
0.73
0.82
9
0.73
0.72
0.77
0.76
1
0
1
1
Revenue
USD
Publication date not stated
176.88M
182.86M
187.44M
8
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
0.71
0.83
0.99
9
0.83
0.83
0.84
0.87
1
0
1
1
Revenue
USD
Publication date not stated
197.40M
201.71M
204.20M
8
 — — — — — — — —
Key facts CIK 1396814 CUSIP 695127100 13F (30d) 54 filings 53 filers Visit website Investor relations